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To the Editor: The Gauging Albuminuria Reduction With
Lotrel in Diabetic Patients With Hypertension (GUARD)
study,1 showed that combination of an angiotensin-convert-
ing enzyme inhibitor (ACEi) with a diuretic significantly
reduced albuminuria more than combination with a calcium
channel blocker in patients with type 2 diabetes. As blood
pressure (BP) is lowered more in combining an ACEi with a
calcium channel blocker, the marked antiproteinuric effects
of combining an ACEi with a diuretic cannot be explained by
BP control. Thus, at least to reduce proteinuria, a diuretic
rather than a calcium channel blocker should be combined
with an ACEi or inhibitors of the renin–angiotensin system
(RAS).
In contrast to albuminuria reduction, the decline in the
glomerular filtration rate (GFR) from the baseline to the end of
the 1-year GUARD1 study was much smaller when an ACEi
was combined with a calcium channel blocker than with
diuretic. Although this finding is often considered unfavorable
for diuretics, we think it opposite. Diuretics suppress tubular
sodium reabsorption, making urinary sodium excretion greater
than intake. As far as BP, glomerular capillary pressure, GFR,
and tubular sodium load remain at the baseline levels, and
sodium balance continues negative, resulting in fall in BP. Once
BP is lowered, glomerular capillary pressure is also lowered,
leading to reductions in both GFR and tubular sodium load.
Under diuretic administration, a steady state of sodium balance
can be achieved only when the GFR and tubular sodium load
are reduced.2 We believe that the decline in GFR in diuretics
reflects lowered glomerular capillary pressure as seen with
renin–angiotensin system inhibitors,3 and therefore may suggest
long-term renoprotection. Diuretics should be used as the
second-line antihypertensive agent for proteinuric patients with
chronic kidney disease, in combination with renin–angiotensin
system inhibitors to reduce proteinuria and to preserve renal
function.
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Current guidelines support the notion that patients with
proteinuric kidney disease should receive a thiazide
diuretic as a second agent, if further blood pressure
reduction is needed.2 There are many studies where
addition of a nondihydropyridine calcium antagonist, that
is, diltiazem provided similar levels of blood pressure
reduction to hydrochlorothiazide. Use of this subclass of
calcium antagonists is also recommended by current
guidelines to reduce blood pressure and proteinuria.2–4
However, in patients with low levels of proteinuria, that is,
generally less than 1 g/day use of any calcium antagonist in
the presence of a blocker of the renin–angiotensin system
can reduce proteinuria.5 The Gauging Albuminuria Re-
duction With Lotrel in Diabetics With Hypertension
(GUARD) Study tested the hypothesis that a fixed-dose
combination of amlodipine/benazepril is more efficacious
in lowering proteinuria than a benazepril/hydrochlorothia-
zide combination.6 Although blood pressure was reduced to a
greater extent with amlodipine/benazepril, proteinuria was
reduced more by benazepril/hydrochlorothiazide. This
study is an example where using a surrogate marker effect
is misleading. A careful look at the data demonstrates that
a significantly greater fall in glomerular filtration rate
resulted in a relatively greater fall in proteinuria in the
benazepril/hydrochlorothiazide group. Given the better
blood pressure reduction without a fall in glomerular
filtration rate in the amlodipine/benazepril group, one
would have to argue for a calcium antagonist as a second-
line agent unless there was a compelling indication for a
diuretic, such as edema or volume overload. In short,
both thiazide diuretics and calcium antagonists get
blood pressure to goal and reduce proteinuria on back-
ground therapy that blocks the renin–angiotensin system,
so either is a viable option depending on the clinical
circumstance.
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In their recent editorial on living kidney donation, Maiorano
and Schena state that ‘several aspects should be discussed by
three different players around a circular and not a rectangular
tableyevery player must assume equal responsibility in the
decision-making process.’1 In our view there are three serious
problems with this model.
The first is that because the potential donor and recipient
would be seated together during the discussion, the results of
the potential donor’s psychosocial and medical evaluations
would be revealed to the potential recipient. Under these
circumstances an ambivalent volunteer might not feel free to
express her reluctance and the possibility of providing a
medical excuse would be eliminated.2,3 The second concern is
that the model requires only a single transplant professional
for both the potential donor and recipient. This approach
presents a clear conflict of interest for the physician.4The
recognition of this problem led an international consensus
group to conclude that ‘transplant centers should make
efforts to assure that the medical and psychosocial assess-
ments and the decision to donate incorporates health care
professional(s) not involved in the care of the recipient.’5
Finally, the decision regarding donor suitability should not be
shared equally among the three parties. Although it is up to
the potential recipient to accept or decline an offer, she
should have no say in the determination of donor
acceptability.
We agree that determining a person’s suitability for living
kidney donation involves complex ethical issues4 but the
authors’ approach only makes matters worse. While living
donation will never be free of ethical concerns, we believe
that the Amsterdam Forum’s endorsement of independent
donor advocates5 who hold private discussions with potential
donors is a major step in the right direction.
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We would like to thank Spital and Taylor1 for the chance to
clarify some important aspects of our Commentary2 on
living kidney donation.
First of all, we think it is important to underline that
the ‘circular table’ should not be seen as a physical entity,
where all the participants of the project sit together and
discuss the donation issue. In our view, the ‘circular table’
should be considered as a dynamic interaction among the
different ‘parts’ involved in the process. In addition, we
agree with many investigators that the transplant team
should involve several experts, ‘nephrologists, surgeons,
living-kidney-donor coordinators, and social workers’, as
we specified in our Commentary. This group of experts
should mediate the interactions between potential donor
and recipient. The sentence about ‘equal responsibility in
the decision-making process’ indicates that each individual
involved in the process of living donation has to assume an
active part in the decision, expressing doubts, questions,
fears, and hopes. In this perspective, the donor’s and
recipient’s risk/benefit profiles should be analyzed by
the transplant professional, and discussed with each one
individually to clarify that both are fundamental for the
correct decision. Finally, public discussion can avoid
the danger of financial gain. In this light, we think that
the delicate ethical aspects concerning living kidney
donation could be correctly faced.
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